You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 159 No. 6, March 22, 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (5)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Lipids and Lipid Disorders
 •Alert me on articles by topic

Forecasting Patient Outcomes in the Management of Hyperlipidemia

Kenneth L. Brier, RPh, MS; John J. Tornow, MD, MBA; Andrea J. Ries, PharmD, BCPS; Mary P. Weber, RPh, MS, BCPS; John R. Downs, MD

Arch Intern Med. 1999;159:569-575.

Background  To forecast adult patient outcomes in the management of hyperlipidemia using adult National Health and Examination Survey III (NHANES III) population statistics and National Cholesterol Education Program (NCEP) guidelines for goals of therapy.

Methods  Review of the hyperlipidemia drug therapy English-language medical literature with emphasis on randomized controlled trials of more than 6 weeks' duration published in the last 7 years, product package inserts, US Food and Drug Administration submission information, and NHANES III population statistics. Data were extracted from studies of lipid-lowering therapy to modify low-density lipoprotein (LDL) levels for primary and secondary prevention of coronary heart disease. The data that were evaluated included sample size, study design, therapeutic intervention, length of study, percentage change in LDL levels, and patient demographics.

Results  Cumulative frequency curves of the LDL distribution among the US adult population were constructed. The mean efficacy of drug therapy from qualified studies was used to extrapolate the percentage of the population expected to respond to the intervention and to forecast the patient outcome.

Conclusions  A useful tool for clinicians was constructed to approximate the percentage of patients, based on risk stratification, who would reach NCEP target goal after a given pharmacotherapeutic intervention to decrease LDL levels.


From Micromedex, Inc, Englewood, Colo (Mr Brier); Foundation Health Federal Services, Inc, Austin, Tex (Dr Tornow); and the Department of Defense Pharmacoeconomic Center, Fort Sam Houston, Tex (Drs Ries and Downs and Ms Weber). Dr Ries is now with the Trinity Valley Medical Center, Palestine, Tex, and Ms Weber is with the Naval Ambulatory Care Center, Groton, Conn.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Long-term Persistence in Use of Statin Therapy in Elderly Patients
Benner et al.
JAMA 2002;288:455-461.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.